Dermatomyositis Completed Phase 2 Trials for Infliximab (DB00065)

Also known as: Dermatomyositides / Dermatopolymyositis, unspecified

IndicationStatusPhase
DBCOND0002234 (Dermatomyositis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00033891Infliximab (Remicade ) to Treat Dermatomyositis and PolymyositisTreatment